USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes

The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.

USPTO Patent Application: Anti-DPP3 Antibody Formulations

The USPTO has published a patent application from 4TEEN4 Pharmaceuticals GmbH for formulations and dosage amounts for administering an anti-DPP3 antibody or fragment thereof to humans. The application, filed on August 26, 2025, details potential treatments for life-threatening circulatory failure conditions such as shock.

USPTO Patent Application: Recombinant Human Type III Collagen for Angiogenesis

The USPTO has published a patent application (US20260083883A1) detailing recombinant human type III collagen designed to promote angiogenesis. The application describes modifications to natural type III collagen to enhance its angiogenic function and adhesion properties, potentially increasing the angiogenesis rate by over 37%.

USPTO Patent Application: Compositions Targeting Endothelial Cells

The USPTO has published a patent application from Harvard College detailing novel compositions for targeting endothelial cells. These compositions, which include binders, linkers, and radioactive isotopes, are intended for selective delivery to cells and treating diseases, including cancer.

USPTO Patent Application for Capsid Polypeptides

The USPTO has published a new patent application (US20260083863A1) from Dyno Therapeutics, Inc. for capsid polypeptides designed for payload delivery. The application details specific polypeptide sequences and their methods of use in therapeutic applications.

USPTO Patent Application: Sustained Transgene Expression of Modified ERT2 Peptide Fusion

The USPTO has published a patent application (US20260083859A1) detailing a novel fusion polypeptide for sustained transgene expression. The application, filed by inventors from various institutions, describes targeting constructs for inducible cell death systems using modified estrogen receptor ligand binding domains.

USPTO Patent Application: Antibody Drug Conjugate Comprising NMT Inhibitor

The USPTO has published a new patent application (US20260083858A1) related to antibody drug conjugates (ADCs) that comprise an NMT inhibitor conjugated to an antibody via a linker. The application details the inventors and abstract of the invention.

USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations

The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.

USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

USPTO Patent Application for Immunoconjugates

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.